Shots:

• The companies collaborate on mapping the immune system's response to threats- including the COVID-19 threat
• The focus of the alliance is to study population-wide immune responses to the COVID-19 with their findings to be publicly available via an open data portal. Following the study of immune responses- the companies expected to provide unique insight for new therapies and diagnostics
• In Apr’2020- Adaptive will begin collecting de-identified blood samples from people diagnosed with COVID-19. Utilizing Adaptive’s technology- researchers will sequence immune cell receptors from the samples and the finding will be analyzed by utilizing Microsoft’s ML and Azure Cloud platform

Click here ­to­ read full press release/ article | Ref: Microsoft | Image: Microsoft